- Record: found
- Abstract: found
- Article: not found
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Geoffrey A Block
1 ,
Kevin J Martin ,
Angel L M de Francisco ,
Stewart A Turner ,
Morrell M Avram ,
Michael G Suranyi ,
Gavril Hercz ,
John Cunningham ,
Ali K Abu-Alfa ,
Piergiorgio Messa ,
Daniel W Coyne ,
Francesco Locatelli ,
Raphael M Cohen ,
Pieter Evenepoel ,
Sharon M Moe ,
Albert Fournier ,
Johann Braun ,
Laura C McCary ,
Valter J Zani ,
Kurt A Olson ,
Tilman B Drüeke ,
William G Goodman
Apr 08 2004
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiving dialysis is often complicated by hypercalcemia and hyperphosphatemia, which may contribute to cardiovascular disease and adverse clinical outcomes. Calcimimetics target the calcium-sensing receptor and lower parathyroid hormone levels without increasing calcium and phosphorus levels. We report the results of two identical randomized, double-blind, placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride.